UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 103

Sortiert nach

New Therapeutic Strategies for Triple-Negative Breast Cancer

Oncology (Williston Park, N.Y.), 2017-02, Vol.31 (2), p.130-137

2017

Link zum Volltext

Verfügbarkeit prüfen

A Phase II Study Evaluating Orteronel, an Inhibitor of Androgen Biosynthesis, in Patients With Androgen Receptor (AR)-Expressing Metastatic Breast Cancer (MBC)

Clinical breast cancer, 2022-04, Vol.22 (3), p.269-278

2022

Link zum Volltext

Verfügbarkeit prüfen

Associations of preoperative breast magnetic resonance imaging with subsequent mastectomy and breast cancer mortality

Breast cancer research and treatment, 2018-11, Vol.172 (2), p.453-461

2018

Link zum Volltext

Verfügbarkeit prüfen

Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer

NPJ breast cancer, 2021-02, Vol.7 (1), p.9-7, Article 9

2021

Link zum Volltext

Verfügbarkeit prüfen

Dermatologic toxicities of chemotherapy: an educational intervention for skin of color women with breast cancer

International journal of women's dermatology, 2023-03, Vol.9 (1), p.e073-e073

2023

Link zum Volltext

Verfügbarkeit prüfen

Abstract PO-078: Introduction of implicit bias training to oncology faculty as a quality improvement initiative

Cancer epidemiology, biomarkers & prevention, 2022-01, Vol.31 (1_Supplement), p.PO-078-PO-078

2022

Link zum Volltext

Verfügbarkeit prüfen

Author Correction: Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer

NPJ breast cancer, 2022-02, Vol.8 (1), p.17-17, Article 17

2022

Link zum Volltext

Verfügbarkeit prüfen

Abstract B091: Introduction of Implicit Bias Training to oncology faculty as a means to improve minority participation in cancer clinical trials

Cancer epidemiology, biomarkers & prevention, 2023-01, Vol.32 (1_Supplement), p.B091-B091

2023

Link zum Volltext

Verfügbarkeit prüfen

Defining Risk of Late Recurrence in Early-Stage Estrogen Receptor-Positive Breast Cancer: Clinical Versus Molecular Tools

Journal of clinical oncology, 2019-06, Vol.37 (16), p.1365-1369

2019

Link zum Volltext

Verfügbarkeit prüfen

Mucosal haemangioma in the setting of treatment with trastuzumab emtansine (T‐DM1)

British journal of dermatology (1951), 2022-11, Vol.187 (5), p.e168-e168

2022

Link zum Volltext

Verfügbarkeit prüfen

Comprehensive cancer control--impacting every physician

Connecticut medicine, 2012-06, Vol.76 (6), p.325

2012

Link zum Volltext

Verfügbarkeit prüfen

Immune microenvironment of triple-negative breast cancer in African-American and Caucasian women

Breast cancer research and treatment, 2019-05, Vol.175 (1), p.247-259

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract 4973: Comparison of tumor immune microenvironment in triple negative breast cancer (TNBC) of African American versus that of white patients

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.4973-4973

2020

Link zum Volltext

Verfügbarkeit prüfen

Increasing accrual of minority patients in breast cancer clinical trials

Breast cancer research and treatment, 2020-11, Vol.184 (2), p.499-505

2020

Link zum Volltext

Verfügbarkeit prüfen

Demographic and clinical factors associated with cardiovascular events in elderly long-term survivors of breast cancer

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e24105-e24105

2023

Link zum Volltext

Verfügbarkeit prüfen

Trends in breast cancer death by stage at diagnoses in 2000-2018

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e18855-e18855

2023

Link zum Volltext

Verfügbarkeit prüfen

Peripheral blood immune parameters, response, and adverse events after neoadjuvant chemotherapy plus durvalumab in early-stage triple-negative breast cancer

Breast cancer research and treatment, 2024-07

2024

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2842: Vesal Yaghoobi

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.2842-2842

2019

Link zum Volltext

Verfügbarkeit prüfen

Quantitative assessment of immune cell populations and associations with clinical outcomes in African-American (AA) versus Caucasian triple-negative breast cancer (TNBC)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e14180-e14180

2019

Link zum Volltext

Verfügbarkeit prüfen

Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast Cancer

Clinical cancer research, 2022-06, Vol.28 (12), p.2587-2597

2022

Link zum Volltext

Verfügbarkeit prüfen

Abstract A089: Addressing both community and institutional barriers increases accrual of minority patients in breast cancer clinical trials

Cancer epidemiology, biomarkers & prevention, 2020-06, Vol.29 (6_Supplement_1), p.A089-A089

2020

Link zum Volltext

Verfügbarkeit prüfen

Randomized Trial of Exercise and Nutrition on Chemotherapy Completion and Pathologic Complete Response in Women With Breast Cancer: The Lifestyle, Exercise, and Nutrition Early After Diagnosis Study

Journal of clinical oncology, 2023-12, Vol.41 (34), p.5285

2023

Link zum Volltext

Verfügbarkeit prüfen

Clinical Outcomes and Immune Markers by Race in a Phase I/II Clinical Trial of Durvalumab Concomitant with Neoadjuvant Chemotherapy in Early-Stage TNBC

Clinical cancer research, 2022-09, Vol.28 (17), p.3720-3728

2022

Link zum Volltext

Verfügbarkeit prüfen

Clinical outcomes and immune markers by race in a phase I/II clinical trial of durvalumab concomitant with neoadjuvant chemotherapy in early-stage TNBC

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.516-516

2022

Link zum Volltext

Verfügbarkeit prüfen

Abstract P5-13-02: Neoadjuvant aromatase inhibitor therapy plus the mTOR inhibitor everolimus in postmenopausal women with hormone receptor positive/HER2 negative breast cancer and an oncotype Dx recurrence score (≤25)

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.P5-P5-13-02

2020

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 103

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(98)
Mit Volltextzugriff
(98)

Publikationsform

Artikel
(101)
Buchkapitel
(2)

Sprache

Englisch
(102)
Japanisch
(3)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

New Therapeutic Strategies for Triple-Negative Breast Cancer

A Phase II Study Evaluating Orteronel, an Inhibitor of Androgen Biosynthesis, in Patients With Androgen Receptor (AR)-Expressing Metastatic Breast Cancer (MBC)

Associations of preoperative breast magnetic resonance imaging with subsequent mastectomy and breast cancer mortality

Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer

Dermatologic toxicities of chemotherapy: an educational intervention for skin of color women with breast cancer

Abstract PO-078: Introduction of implicit bias training to oncology faculty as a quality improvement initiative

Author Correction: Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer

Abstract B091: Introduction of Implicit Bias Training to oncology faculty as a means to improve minority participation in cancer clinical trials

Defining Risk of Late Recurrence in Early-Stage Estrogen Receptor-Positive Breast Cancer: Clinical Versus Molecular Tools

Mucosal haemangioma in the setting of treatment with trastuzumab emtansine (T‐DM1)

Comprehensive cancer control--impacting every physician

Immune microenvironment of triple-negative breast cancer in African-American and Caucasian women

Abstract 4973: Comparison of tumor immune microenvironment in triple negative breast cancer (TNBC) of African American versus that of white patients

Increasing accrual of minority patients in breast cancer clinical trials

Demographic and clinical factors associated with cardiovascular events in elderly long-term survivors of breast cancer

Trends in breast cancer death by stage at diagnoses in 2000-2018

Peripheral blood immune parameters, response, and adverse events after neoadjuvant chemotherapy plus durvalumab in early-stage triple-negative breast cancer

Abstract 2842: Vesal Yaghoobi

Quantitative assessment of immune cell populations and associations with clinical outcomes in African-American (AA) versus Caucasian triple-negative breast cancer (TNBC)

Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast Cancer

Abstract A089: Addressing both community and institutional barriers increases accrual of minority patients in breast cancer clinical trials

Randomized Trial of Exercise and Nutrition on Chemotherapy Completion and Pathologic Complete Response in Women With Breast Cancer: The Lifestyle, Exercise, and Nutrition Early After Diagnosis Study

Clinical Outcomes and Immune Markers by Race in a Phase I/II Clinical Trial of Durvalumab Concomitant with Neoadjuvant Chemotherapy in Early-Stage TNBC

Clinical outcomes and immune markers by race in a phase I/II clinical trial of durvalumab concomitant with neoadjuvant chemotherapy in early-stage TNBC

Abstract P5-13-02: Neoadjuvant aromatase inhibitor therapy plus the mTOR inhibitor everolimus in postmenopausal women with hormone receptor positive/HER2 negative breast cancer and an oncotype Dx recurrence score (≤25)

Suchergebnisse filtern